MAF

DELFI Diagnostics Announces Availability of New Fragmentome-Based Cancer Treatment Monitoring Assay

Retrieved on: 
Thursday, February 1, 2024
Liquid biopsy, MAF, Immunocore, Research, Clonal hematopoiesis, PALO, Patient, DELFI, TCR, ImmTAC, RUO, Neoplasm, Cancer, Plasma, Nucleic acid thermodynamics

PALO ALTO, Calif. and BALTIMORE, Feb. 1, 2024 /PRNewswire/ -- DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to enhance cancer detection, today announced availability of the company's fragmentome-based research use only (RUO) cancer monitoring assay. The DELFI-Tumor Fraction (DELFI-TF) assay is a highly sensitive, inexpensive means of noninvasive measurement of tumor burden and assessing treatment response and resistance in patients with advanced cancer.

Key Points: 
  • PALO ALTO, Calif. and BALTIMORE, Feb. 1, 2024 /PRNewswire/ -- DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to enhance cancer detection, today announced availability of the company's fragmentome-based research use only (RUO) cancer monitoring assay.
  • The DELFI-Tumor Fraction (DELFI-TF) assay is a highly sensitive, inexpensive means of noninvasive measurement of tumor burden and assessing treatment response and resistance in patients with advanced cancer.
  • Additionally, DELFI announced a new research collaboration with Immunocore Holdings plc (Nasdaq: IMCR) – a commercial-stage biotechnology company pioneering the development of a novel class of bispecific T cell receptor (TCR) immunotherapies against cancer (ImmTAC molecules) – focused on exploring the use of the DELFI-TF cancer monitoring assay as an early predictor of benefit from treatment with ImmTAC-based therapies.
  • "We are excited that Immunocore will be further exploring the clinical and research potential of the DELFI liquid biopsy platform as a new approach to monitoring treatment response."

NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID)

Retrieved on: 
Tuesday, December 12, 2023
Long COVID, Long, CDC, Baylor University, Baylor College of Medicine, COVID-19, Division, Infection, FDA, Pain, ACR, Gait, Cough, Weakness, PACS, Clinical trial, Quell, NSF, MAF, National Science Foundation, Fibromyalgia, American College, Myalgia, Patient, Safety, Memory, BPI, Arthralgia, Pharmaceutical industry

The trial was conducted at the Baylor College of Medicine in collaboration with C2SHIP.

Key Points: 
  • The trial was conducted at the Baylor College of Medicine in collaboration with C2SHIP.
  • The principal investigator was Dr. Bijan Najafi, Professor of Surgery, and clinical director at the Division of Vascular Surgery and Endovascular Therapy, Baylor College of Medicine.
  • According to the Centers for Disease Control and Prevention (CDC), about 10 million Americans have PACS.
  • "This pilot trial suggests that Quell may alleviate fibromyalgia-like pain and other symptoms of Long Covid.

Glen A. Taylor Announces Start of New Charitable Legacy Plan

Retrieved on: 
Tuesday, December 19, 2023
Children, Philanthropy, Family, Fund Raising, Consumer, Other Philanthropy, Foundation, Agriculture, Natural Resources, Lynx, Partnership, Education, Paul the Apostle, History, CST, MAF, Minnesota Timberwolves, Organization, Management

Glen Taylor has announced the start of a new charitable legacy plan that will fund a wide range of philanthropic activities for decades to come.

Key Points: 
  • Glen Taylor has announced the start of a new charitable legacy plan that will fund a wide range of philanthropic activities for decades to come.
  • “The good people of this region have been crucial to my personal growth and success of my businesses,” said Taylor.
  • The gift will create a financial framework to support these and other causes for future generations in the area Glen Taylor still calls home.
  • “These three organizations were hand-picked because of their regional expertise and their shared focus on creating vibrant communities,” added Taylor.

Students Across the Globe Awarded Top Honors During CME Group's University Trading Challenge

Retrieved on: 
Thursday, November 30, 2023
Agriculture, MAF, Risk management, Metal, CQG, CME Group, Student, Communication, Dow Jones, Marketing, Specialist, University, Life, SVP, Auction

Students learned hands-on techniques for trading agriculture, energy, metals, equity indices, interest rates and foreign exchange futures contracts using CQG 's real-time simulated electronic trading platform.

Key Points: 
  • Students learned hands-on techniques for trading agriculture, energy, metals, equity indices, interest rates and foreign exchange futures contracts using CQG 's real-time simulated electronic trading platform.
  • "We congratulate the students from around the world who participated in our 20th CME Group University Trading Challenge," said Anita Liskey, CME Group Senior Managing Director of Global Brand Marketing and Communications.
  • "Congratulations to all of the winners and participants in this year's University Trading Challenge," said Pat Kenny, SVP of Client Relations at CQG.
  • "CME Group's University Trading Challenge motivates students and opens their minds to immense opportunities," said Maf.

Polyplastics Announces Commercial Availability of DURACON (R) POM PM Series for Medical Industry

Retrieved on: 
Thursday, June 22, 2023
GMP, Kahr PM series, COC, EU, Food, Ethylene oxide, ISO, MAF, CFR, VDI, USP, Sterilization, ISO 10993, Miniaturization, DMF, FDA, POM, Polymer, Thermoplastic, Medical device

TOKYO, June 22, 2023 /PRNewswire/ -- The Polyplastics Group is pleased to announce the commercial availability of its DURACON (R) POM (Polyoxymethylene/Acetal) PM Series for medical applications.

Key Points: 
  • TOKYO, June 22, 2023 /PRNewswire/ -- The Polyplastics Group is pleased to announce the commercial availability of its DURACON (R) POM (Polyoxymethylene/Acetal) PM Series for medical applications.
  • Polyplastics has served the medical and healthcare field for decades with its high-purity TOPAS (R) COC (cyclic olefin copolymer).
  • As the world's leading POM manufacturer, Polyplastics now adds the PM Series to its medical grade portfolio and plans to expand material supply to the medical and healthcare market.
  • Polyplastics' two acetal grades include a standard viscosity grade, PM09S01N, which delivers the reliable mechanical properties and moldability expected from POM.

Polyplastics Announces Commercial Availability of DURACON (R) POM PM Series for Medical Industry

Retrieved on: 
Thursday, June 22, 2023
GMP, Kahr PM series, COC, EU, Food, Ethylene oxide, ISO, MAF, CFR, VDI, USP, Sterilization, ISO 10993, Miniaturization, DMF, FDA, POM, Polymer, Thermoplastic, Medical device

TOKYO, June 22, 2023 /PRNewswire/ -- The Polyplastics Group is pleased to announce the commercial availability of its DURACON (R) POM (Polyoxymethylene/Acetal) PM Series for medical applications.

Key Points: 
  • TOKYO, June 22, 2023 /PRNewswire/ -- The Polyplastics Group is pleased to announce the commercial availability of its DURACON (R) POM (Polyoxymethylene/Acetal) PM Series for medical applications.
  • Polyplastics has served the medical and healthcare field for decades with its high-purity TOPAS (R) COC (cyclic olefin copolymer).
  • As the world's leading POM manufacturer, Polyplastics now adds the PM Series to its medical grade portfolio and plans to expand material supply to the medical and healthcare market.
  • Polyplastics' two acetal grades include a standard viscosity grade, PM09S01N, which delivers the reliable mechanical properties and moldability expected from POM.

Sermonix Pharmaceuticals Shares ASCO Poster Presentation on Longer Patient Follow-up Results for ELAINE-2 Study in ESR1-mutated Metastatic Breast Cancer

Retrieved on: 
Monday, June 5, 2023
Therapy, Diarrhea, Progression-free survival, MAF, Survival, RECIST, Woman, Mutation, CBR, PFS, Trial of the century, Eli Lilly, ASCO, Vomiting, American Society of Clinical Oncology, Patient, Annual general meeting, Nausea, Poster, Society, ORR, Fatigue, Pharmaceutical industry, Birth control, Nursing, Dietary supplement, Lasofoxifene, ESR1

CHICAGO, June 05, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, today broadly shared a poster presentation detailing the results of its ELAINE-2 clinical study with longer patient follow-up.

Key Points: 
  • CHICAGO, June 05, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, today broadly shared a poster presentation detailing the results of its ELAINE-2 clinical study with longer patient follow-up.
  • The poster was initially presented yesterday at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • “No new safety signals were noted when looking at lasofoxifene and abemaciclib with longer patient follow-up,” said Paul Plourde, M.D., vice president of oncology clinical development at Sermonix.
  • Sermonix in March initiated ELAINE-3, a registrational Phase 3 study of 400 patients assessing the efficacy of lasofoxifene and abemaciclib.

Forrester Recognises Majid Al Futtaim As EMEA Recipient Of 2023 Customer-Obsessed Enterprise Award

Retrieved on: 
Thursday, April 20, 2023
Retail, Content Marketing, Other Communications, Publishing, Public Relations, Investor Relations, Marketing, Consulting, Advertising, Communications, Business, Professional Services, Other Retail, Media, Specialty, Digital Marketing, MAF, CX, Forrester, FORR

Forrester (Nasdaq: FORR) today announced that retail holding company Majid Al Futtaim (MAF) is the Europe, Middle East, and Africa (EMEA) winner of its inaugural Customer-Obsessed Enterprise Award.

Key Points: 
  • Forrester (Nasdaq: FORR) today announced that retail holding company Majid Al Futtaim (MAF) is the Europe, Middle East, and Africa (EMEA) winner of its inaugural Customer-Obsessed Enterprise Award.
  • The award recognises organisations that are putting customers at the centre of everything they do to accelerate business growth, retain customers, and enable greater employee engagement.
  • MAF will be honoured at CX EMEA , being held in London and digitally, May 10–11, 2023.
  • “We congratulate MAF for winning Forrester’s Customer-Obsessed Enterprise Award for EMEA,” said Martin Gill, vice president and research director at Forrester and host of CX EMEA.

DELFI Diagnostics Presents Additional Promising Proof-of-Concept Data on its Monitoring Program at AACR 2023

Retrieved on: 
Tuesday, April 18, 2023
AACR, CRC, Progression-free survival, MAF, DELFI, Georgetown University Medical Center, ESMO, Survival, Married at First Sight (American TV series), Netherlands Cancer Institute, Cancer, Lung cancer, American Association for Cancer Research, BRAF, Prognosis, Immunotherapy, Doctor of Philosophy, Translational Research Institute (Australia), University Medical Center Utrecht, RAS, MD, Patient, Translational research, Annual general meeting, HR, Knowledge, Neoplasm, Ovarian cancer, Gene, Medical imaging, Pharmaceutical industry

The data were presented at the American Association for Cancer Research (AACR) 2023 Annual Meeting and builds on earlier studies showing the potential of using DELFI's technology for treatment monitoring.

Key Points: 
  • The data were presented at the American Association for Cancer Research (AACR) 2023 Annual Meeting and builds on earlier studies showing the potential of using DELFI's technology for treatment monitoring.
  • The study builds on prior work demonstrating the potential of the DELFI platform to monitor patients with metastatic cancer undergoing treatment with immunotherapy.
  • Also at AACR, DELFI and other researchers using the DELFI platform presented data describing the platform's strong performance in a training set that will be used to develop DELFI's first lung cancer screening product.
  • Researchers also shared promising initial data on the DELFI platform's ability to detect early stage ovarian cancer.

Statement on release of MAF pilot Ryan Koher from prison in Mozambique

Retrieved on: 
Thursday, March 16, 2023
Aviation, Mission Aviation Fellowship, Family, African, MAF, Hope, Organization, Airline

GUELPH, Ontario, March 16, 2023 (GLOBE NEWSWIRE) -- Mission Aviation Fellowship (MAF) is pleased to confirm that pilot Ryan Koher has been granted a provisional release from prison in Mozambique.

Key Points: 
  • GUELPH, Ontario, March 16, 2023 (GLOBE NEWSWIRE) -- Mission Aviation Fellowship (MAF) is pleased to confirm that pilot Ryan Koher has been granted a provisional release from prison in Mozambique.
  • Koher, an American pilot, along with two South African men, W.J.
  • We ask for continued prayer that the final outcome will be a full release of Ryan from any charges and trial.
  • Out of respect for the legal process in Mozambique, MAF will make no further comment at this time.